We analyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who experienced virologic failure in clinical trials of direct-acting antivirals. We demonstrated that 97% had post-treatment Week 12 HCV RNA >10 000 IU/mL, above reported sensitivity limits of novel diagnostic assays being considered for simplified HCV treatment monitoring.
Keywords: HCV RNA; HCV core antigen; direct-acting antivirals; hepatitis C virus; relapse.
Published by Oxford University Press for the Infectious Diseases Society of America 2019.